2014 EASO Position Statement on the Use of Anti-Obesity Drugs
Open Access
- 1 May 2015
- journal article
- research article
- Published by S. Karger AG in Obesity Facts
- Vol. 8 (3) , 166-174
Abstract
The European Association for the Study of Obesity (EASO) considers obesity to be a health, research, and societal priority [1]. It promotes the study of obesity. Moreover, the EASO facilitates and engages in actions that reduce the burden of unhealthy excess weight in Europe through prevention as well as management and prevent and combat the epidemic of obesity.Keywords
This publication has 36 references indexed in Scilit:
- Modern Obesity Pharmacotherapy: Weighing Cardiovascular Risk and BenefitClinical Cardiology, 2014
- Medical treatment of obesity: The past, the present and the futureBest Practice & Research Clinical Gastroenterology, 2014
- An EASO Position Statement on Multidisciplinary Obesity Management in AdultsObesity Facts, 2014
- Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramateDiabetes, Metabolic Syndrome and Obesity, 2014
- Long-term Drug Treatment for ObesityJAMA, 2014
- Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical managementExpert Opinion on Drug Safety, 2013
- Anti-obesity drugs: past, present and futureDisease Models & Mechanisms, 2012
- Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potentialObesity Reviews, 2011
- Criteria for EASO-Collaborating Centres for Obesity ManagementObesity Facts, 2011
- Management of Obesity in Adults: European Clinical Practice GuidelinesObesity Facts, 2008